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The manganese doped zinc selenide nanoparticles (ZnSe:Mn NPs) have been synthesized by thermolysis method using 
oleic acid and oleylamine as capping agents, and 1-octadecene as solvent. Coating of mesoporous silica is done on ZnSe:Mn 
(ZnSe:Mn@mSilica) which is further functionalized with amine functional groups by treating with 
(3-aminopropyl)trimethoxysilane. Further pegylation is done to achieve water dispersibility by conjugating carboxyl groups 
of poly(ethylene glycol) diacid with the amine groups. These pegylated NPs are subsequently treated with ethylenediamine 
followed by acrylic acid. Conjugation of tris-(hydroxymethyl-aminomethane) is performed by Michael-type addition 
reaction to afford ZnSe:Mn@mSilica-PEG-Tris-OH. These tris functionalized NPs have exhibited broad emission ranging 
from 590-620 nm that is an indicative for their suitability in diagnosis and monitoring progress of cancer treatment. To 
explore the usefulness of increased surface area because of mesoporosity, doxorubicin is loaded on ZnSe:Mn@mSilica-
PEG-Tris-OH NPs through silyl ether linkage and evaluated for cytotoxicity against WEHI-164 mouse fibrosarcoma and 
RAJI human hematopoietic origin cancer cell lines. A decrease in 12% of cell viability of WEHI-164 cells while 30% 
decrease in RAJI cell lines (IC50 ≈ 45 nM) are observed. This shows that our formulation has more cytotoxic in RAJI cancer 
cell lines than that of WEHI-164 cancer cells. These results reveal that the formulation has potential for the application in 
drug delivery and diagnosis in chemotherapeutics. 
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The quest of luminescent nanoparticles (NPs) for 
using clinically as optical bio-imaging agents as well 
as drug delivery vehicles in diagnosis and therapy of 
many diseases especially cancer, has been recognized 
as major frontier research area1. Initially fluorescent 
organic dyes2 have been conjugated with drug 
delivery vehicles like liposomes, micelle, and silica 
based NPs3. But unlike conventional organic 
fluorophore, the luminescent NPs possess distinct 
photophysical properties, like broad excitation, size-
tunable emission and high photostability rendering 
them promising fluorescent imaging agents. The 
surface functionalization of such NPs with specific 
biological moieties enables loading of drug, drift to 
cancer site and deliver drugs at cancer site. It was 
observed that the use of biological moieties that can 
sense specific physiological conditions like acidic pH 
of tumor site reduces the side effect with the increased 
therapeutic index. In addition to these, the 
luminescence property enables them a suitable modality 
for theranostic use, an emerging therapeutic paradigm4. 
In this perspective, various types of NPs based 
formulations were developed5. Among them, NPs 
with inorganic origin such as carbon nanotubes, gold 
nanoparticles and especially quantum dots of some 
semiconductor materials are main focus. 
Semiconducting inorganic nanocarriers have 
exhibited potential to be used for many biomedical 
applications, like drug delivery, cellular imaging6 and 
in photodynamic therapy for cancer treatment7. 
Mainly semiconductor based NPs mostly in the form 
of quantum dots (QDs) that are made up from groups 
II-IV, III-V or IV-VI like CdSe, CdS, CdTe, PbSe,
GaAs, InP, InAs, etc. were employed because of their
exclusive electronic and optical properties8. However,
toxicity originated from heavy metals like cadmium,





lead, or arsenic, which are deteriorated from the 
lattice into biological systems if the surfaces are not 
properly protected by the shells or ligands, has limited 
their practical biomedical applications9. Additionally, 
the major concern for the use of QDs in biological 
applications is inability to cross the cell membrane 
owing to their size and chemical nature and 
nonspecific cellular binding of quantum dots10,11.  
In view of these drawbacks, the researchers have 
developed NPs based on heavy metals other than 
Cd12. Among them, ZnSe based materials like zinc 
chalcogenides doped with Mn2+, Eu2+, Cu2+, or Ga2+ 
exert low intrinsic toxicity and exclusive 
photophysical properties13,14. The cytotoxicity 
evaluations for these ZnSe NPs have revealed their 
suitability for biological applications ranging from 
diagnosis to drug delivery as evidenced for their non-
toxicity up to certain concentration15,16.  
Considering these facts, Mn doped ZnSe 
luminescent NPs were synthesized and coated with 
mesoporous silica with objective of loading 
doxorubicin (adriamycin) in maximum amount by 
increased surface area due to porous nature of 
mesoporous silica17,18,19. The loading of doxorubicin 
was done after functionalization using synthetic 
chemistry strategies and evaluated for cytotoxicity 
against Burkitt's lymphoma cancer cells (RAJI)-
human hematopoietic origin cancer cell lines and 
Walter and Eliza Hall Institute (WEHI-164)-mouse 
fibrosarcoma cancer cell lines. The drug release kinetics 
was also evaluated. The results are reported herein. 
 
Materials and Methods 
The elemental selenium (Se), 3-bromopropionic acid, 
sodium borohydride (NaBH4), oleic acid, 1-octadecene, 
oleylamine, zinc acetate dihydrate [Zn(OAc)2.2H2O], 
manganese acetate tetrahydrate [Mn(OAc)2.4H2O], 
polyoxyethylene (5) nonylphenylether (IGEPAL-CO 
500), cetyl trimethyl ammonium bromide (CTAB), 
tetraethyl orthosilicate (TEOS), ammonia solution 
(30%), (3-aminopropyl)trimethoxysilane (APTMS), 
polyethylene glycol (PEG) diacid, tris- 
(hydroxymethyl)aminomethane hydrochloride (Tris 
HCl), dimethyldichlorosilane (DMDCS) and N,N'-
dicyclohexylcarbodiimide (DCC), 4-
dimethylaminopyridine (DMAP) and doxorubicin 
(Dox) were purchased from commercial sources. All 
reactions were performed under an inert atmosphere 
of argon (Ar). The selenium compound, 
(SeCH2CH2COOH)2 was synthesized and purified by 
recrystallization in hot water. The solvents were 
purified by standard procedures and were distilled 
prior to use20. The melting point was determined in 
capillary tube and is uncorrected. Elemental analysis 
was carried out on Flash EA 1112 Series CHNS 
analyzer. NMR spectra were recorded on a Bruker 
Ascend™ 400 MHz spectrometer operating at 400.13 
(1H), 100.61 (13C{1H}) and 76.31 MHz (77Se{1H}) in 
DMSO-D6. 1H and 13C{1H} NMR chemical shifts are 
relative to internal DMSO peak. The 77Se{1H} NMR 
chemical shifts were relative to external Ph2Se2 in 
CDCl3 (δ 463.0 ppm relative to Me2Se (0 ppm). The 
powder X-ray diffraction (XRD) patterns were 
recorded on a PANalytical X′pert PRO X-ray 
diffractometer using Cu-Kα radiation in the 2θ range 
of 10-70° with step size 0.02° and time gap of 1.20 s. 
The XRD patterns were analyzed by comparing with 
standard reported data. The transmission electron 
microscopic (TEM) image was recorded on Libra-120 
plus TEM (Carl Zeiss, Germany) operated at 120 kV. The 
cancer cell lines viz., mouse BALB/c, fibrosarcoma 
(WEHI-164) and human hematopoietic origin cancer cell 
lines (RAJI) were obtained from the National Center for 
Cell Sciences (NCCS), Pune, India. The cytotoxicity of 
formulation was evaluated using flow cytometer - Guava 
Flow cytometer (Luminex Corporation, USA). 
 
Synthesis of 3, 3′-diselenodipropionic acid [(SeCH2CH2COOH)2]21 
In a three-necked round bottom flask, the  
elemental selenium (1.5 g, 19.00 mmol) suspended  
in distilled water and NaBH4 (0.72 g, 19.95 mmol) 
were reacted by stirring and followed by refluxing  
for 30 min and then cooling to room temperature. To 
this, the 3-bromopropionic acid (2.90 g, 19.00 mmol) 
was added. The reaction mixture was stirred further 
for 2 h till the formation of a yellow precipitate, 
worked up with diethyl ether (3 × 50 mL) and  
then concentrated in vacuo to afford the yellow 
powder which was recrystallized in hot water to 
afford pale yellow crystalline solid product, 
[(SeCH2CH2COOH)2] (2.4 g, 83 %) in optimum  
yield. M. p. 142 °C. Analysis Calcd. for C6H10O4Se2: C, 
23.70, H, 3.30%; Found: C, 23.30, H, 3.20%. 1H NMR 
(DMSO-D6) δ: 2.74 (t, J = 6.9 Hz, 2 H, SeCH2), 3.04 (t, J 
= 6.9 Hz, 2 H, SeCH2CH2); 13C{1H} NMR (DMSO-D6) 
δ: 24.2 (JSe-C = 75.0 Hz, SeCH2), 35.7 (SeCH2CH2), 173.4 
(C=O); 77Se{1H} NMR (DMSO-D6) δ: 316 ppm. 
 
Synthesis of Mn doped ZnSe NPs 
In a three-necked round bottom flask, zinc  
acetate (0.5 g), (SeCH2CH2COOH)2 (2.02 g) and 
manganese acetate (20 mg) were mixed with oleic 
acid (4 mL), oleylamine (15 mL) and 1-octadecene 





(30 mL). In the inert atmosphere of argon, the 
reaction mixture was allowed to dissolve and  
heated slowly with the heating rate of 4 °C per minute 
till 320 °C. During the heating process, changes in  
the appearance of the reaction mixture to a yellow 
coloured solution at 150 °C and then to dark red at  
250 °C were observed. After heating at 320 °C  
for 2 h and cooling to room temperature, the NPs 
were precipitated out by addition of acetone (~100 mL) 
in excess, collected by centrifugation and washed 
repeatedly (3-4 times) with acetone. After drying 
under an IR (Infrared) lamp, the NPs were 
characterized with powder XRD and TEM analyses. 
 
Coating of mesoporous silica on Mn doped ZnSe NPs: 
ZnSe:Mn@mSilica22  
To oleic acid coated ZnSe:Mn NPs (200 mg) 
dispersed in cyclohexane (4 mL), cetyl trimethyl 
ammonium bromide (CTAB, 800 mg) dissolved in 
water (20 mL) was added and stirred for overnight  
till the clearly transparent solution was observed. 
After adjusting the pH of the solution to 11 by 
controlled addition of ammonia solution (500 µL), 
TEOS (1.5 mL) was added slowly over a period 1 h. 
After stirring the reaction mixture at 60 °C for 1 h and 
stirring at room temperature for 5 h, the NPs were 
collected. For getting mesoporosity in the NPs, 
removal of CTAB was done by solvent extraction 
method using ethanolic ammonium nitrate solution. 
The obtained ZnSe:Mn@mSilica NPs were collected 
by centrifugation and characterized by TEM analysis. 
 
Functionalization of mesoporous silica coated over Mn doped 
ZnSe nanoparticles: ZnSe:Mn@mSilica-NH2 
In a round bottom flask containing nanoparticles 
(ZnSe:Mn@mSilica) (300 mg) dispersed in dried toluene 
(5 mL), APTMS (2 mL) and triethylamine (1 mL) 
were added and the reaction mixture was stirred for 
overnight (~ 10 h). The functionalized NPs, 
ZnSe:Mn@mSilica-NH2 were collected by centrifugation 
and washed with ethanol and finally with acetone. 
 
Synthesis ZnSe:Mn@mSilica-PEG 
In a round bottom flask, PEG-diacid (200 mg) was 
treated with DCC (900 mg) at 0 °C in DMF 
(dimethylformamide) (5 mL). After stirring for 6 h at 
room temperature, ZnSe:Mn@mSilica-NH2 NPs (200 
mg) and catalytic amount of DMAP were added, 
stirred for another 6 h and followed by addition of 
excess ethylenediamine (2 mL). After stirring for 
overnight, the NPs were obtained by centrifugation, 
washed with acetone and dried under an IR lamp.  
Synthesis of ZnSe:Mn@mSilica-PEG-Acrylic 
In a round bottom flask, the NPs of 
ZnSe:Mn@mSilica-PEG (126 mg) were dispersed in 
DMF (5 mL). In another round bottom flask 
containing acrylic acid (200 mg, 140 μL), DCC (859 mg) 
was added at 0 °C, transferred to the round bottom 
flask containing the dispersed NPs and stirred at room 
temperature. After stirring the reaction mixture for 
overnight, the NPs were collected by centrifugation, 
washed with acetone, dried under an IR lamp and 
characterized with FT-IR spectroscopy (υ in cm-1): 
3700, 1690, 1540, 800. 
 
Tris functionalization: ZnSe:Mn@mSilica-PEG-Tris-OH 
To acrylic functionalized NPs, ZnSe:Mn@mSilica-
PEG-Acrylic (100 mg) dispersed in methanol  
(10 mL), tris-(hydroxymethyl-aminomethane) (250 mg) 
and sodium bicarbonate (500 mg) were added and 
stirred. After stirring for overnight, NPs were 
collected by centrifugation, washed with acetone and 
dried under an IR lamp. The NPs were characterized 
with FT-IR spectroscopy (υ in cm-1): 3277, 2890, 
1655, 1556, 1054, 795, 455. 
 
Preparation of formulation: Loading of Dox over surface 
functionalized ZnSe:Mn@mSilica-PEG-Tris-O-Si(Me2)-O-Dox 
To the ZnSe:Mn@Silica-PEG-Tris-OH NPs  
(25 mg) dispersed in dry DMF (2 mL), a large excess 
of DMDCS (1 mL) and imidazole (5 mg) were added 
at room temperature. The reaction mixture was  
stirred for overnight (≈ 10 h). Then this reaction 
mixture was centrifuged followed by washing with 
DMF (2 × 5 mL) and collected the NPs. These NPs 
were further dispersed in dry DMF (2 mL) followed 
by addition of doxorubicin (2 mg) and imidazole  
(4 mg) under subdued light conditions. Then the 
reaction mixture was covered with aluminium foil to 
protect from light. After stirring for 5 h, the NPs  
were collected by centrifugation, and then washed 
with ethanol (5 mL) till there was no colour of  
Dox persisted in supernatant. The NPs (20 mg)  
were dried in vacuo and then characterized by FT-IR 
and UV-visible absorption spectroscopy. TEM images 
were taken by placing a drop of well dispersed NPs  
in hexane onto a carbon coated copper grid and  
after drying under vacuum.  
 
Cytotoxicity evaluation of ZnSe:Mn@mSilica-PEG-Tris-O-




WEHI-164 mouse fibrosarcoma cell lines and  
RAJI human hematopoietic origin cancer cell lines 





were obtained from the National Center for Cell 
Sciences (NCCS) Pune, India and cultured in  
DMEM (Dulbecco's Modified Eagle Medium) and 
RPMI (Roswell Park Memorial Institute) medium, 
respectively, that were supplemented with 10% serum 
(Invitrogen Corporation, CA, USA) and antibiotic 
solution. Cells were grown in humidified 5% CO2 
atmosphere in incubator at 37 °C and were passaged 
for every alternate day. 
 
Cytotoxicity studies 
The cytotoxicity of ZnSe:Mn@mSilica-PEG- 
Tris-O-Si(Me2)-O-Dox and control NPs i.e., 
ZnSe:Mn@mSilica-PEG-Tris-OH was evaluated 
against WEHI-164 mouse fibrosarcoma and RAJI 
human hematopoietic origin cancer cell lines using 
flow cytometer. Around 0.1 million cells were seeded 
in each well of a 96 well plate and incubated for 
overnight in humidified incubator with 5% CO2. The 
test compounds were prepared in PBS. The cells were 
treated with concentration of 20 nM and 50 nM for  
48 h. The cells were harvested, washed with PBS and 
re-suspended in 1 mL of PBS. Around 20 μL of cell 
suspension was mixed with 20x of Guava cell 
viability reagents. Samples were analyzed on flow 
cytometer. The viability was expressed as absolute 
percentage of viable and dead cells. 
 
Results and Discussion 
Various synthetic methods have been reported for 
synthesis of Mn doped ZnSe (ZnSe:Mn) based NPs, 
nanotubes, nanosheets, microflower or colloidal form 
or its core-shell analogues. Some of prominent 
methods are microwave-assisted solvothermal 
method, hydrothermal method24-27, thermolysis28 or 
simple thermal treatment29 and use of simple 
chemicals30. We have employed thermolysis of 
organoselenium compound, (SeCH2CH2COOH)2 along 
with Zn and Mn compounds using oleylamine and oleic 
acid as capping agents and 1-octadecene solvent at  
320 °C for synthesis of ZnSe:Mn NPs (Scheme 1).  
The obtained NPs were characterized with powder 
XRD analysis. Three diffraction peaks observed at 2θ: 
28.6°, 47.8° and 55.8° matched with corresponding 
planes i.e., (111), (220) and (311) lattice planes of the 
standard cubic zinc blende structure (JCPDS file No. 
80-0021; Fig. 1). The morphology of well dispersed, 
sonicated ZnSe:Mn NPs was studied with TEM 
imaging (Fig. 2a) and found to have the spherical NPs 
with uniform shape and size of 10 nm. This shows 
that the NPs are monodisperesed (uniform size) which 
is the required property for biological applications31. 
The coating of these NPs by oleic acid renders 
them hydrophobic and unsuitable for biological 
applications. To make biocompatibility for health 
related applications; usually transfer to hydrophilic 
form from hydrophobic can be achieved by surface 
modifications32. Hence, we coated NPs with 
mesoporous silica by a modified Stöber et al., method 
producing ZnSe:Mn@SiO2 NPs. The characterization 
was done by powder XRD which revealed the 
formation of cubic phase ZnSe (JCPDS PDF no. 
 01-088-2345) with SiO2 (JCPDS PDF no. 821576) 
(Fig. 1). The confirmation of silica shell above ZnSe 
NPs was done by TEM image (Fig. 2b) due to the 
difference in the refractive index of the shell (SiO2) 
and the core (ZnSe:Mn). Determination of the 
thickness of the shell and overall size of the NPs was 
done statistically by employing hundred NPs. The 
thickness of the shell was found to be in the range of 
60±1 nm and overall size of the NPs was in the range 
of 70±10 nm. The ZnSe:Mn@SiO2 NPs were further 
functionalized with -NH2 functional groups by 
treatment of ZnSe:Mn@mSiO2 with APTMS in basic 
medium. The amine functional groups present on the 
ZnSe:Mn@SiO2-NH2 were characterized by FT-IR 
spectroscopy (Fig. 3). The bands at 1035 cm-1 are 
assigned for Si-O-Si symmetrical and asymmetrical 
stretching33. The bands at 780 cm-1 (N-H wag),  
1650 cm-1 (N-H bending) and the broad band centered 
at 3300 cm-1 confirm the presence of amine groups  
on the surface of ZnSe:Mn@SiO2-NH234.  
Using amine functional groups on the surface of 
ZnSe:Mn@SiO2-NH2 NPs, pegylation was performed 
by PEG-diacid to afford the water dispersible and 
PEG functionalized NPs (ZnSe:Mn@mSilica-PEG)35. 
One of the carboxyl groups was attached to the NPs 
and another carboxyl group was free. The free 
carboxyl group was allowed to react with 
ethylenediamine forming amine functionalized NPs. 
They were further treated with acrylic acid to obtain 
ZnSe:Mn@mSilica-PEG-Acrylic NPs36. Further 
treatment with tris(hydroxymethylaminomethane) in 
methanolic solution in presence of sodium 
bicarbonate yielded the ZnSe:Mn@Silica-PEG-Tris-
OH. These NPs were characterized with FT-IR 
spectroscopy as well as photoluminescence. The 
presence of broad peaks centered at 1673 cm-1 and 
3432 cm-1 confirm the formation of the 
functionalization. When photoluminescence studies 





were conducted, broad emission at the range of  
580-615 nm wavelengths was observed (Fig. 4). It is 
indicative that the said NPs have potential for bio-
imaging in diagnosis and treatment in desired area of 
anticancer applications. 
The tris functionalized NPs were treated with 
DCDMS to render the intermediate with silyl 
compound which further treated with Dox to load the 
Dox through silyl ether bond. The formulation, 
ZnSe:Mn@mSilica-PEG-Tris-O-Si(Me2)- O-Dox was 
confirmed by FT-IR spectroscopy. The presence of 
broad peak centered at 1636 cm-1 for C=O of amide of 
ZnSe:Mn@mSilica-PEG-Tris-O-Si(Me2)-O-Dox and 
carbonyl of Dox and 3363 cm-1 from O-H stretching 
vibrations. The presence of peak at 3021 cm-1 for C-H 
stretching vibration of aromatic carbons of Dox also 
further confirmed the loading. The amount of Dox 




Scheme 1 ― Schematic representation for the synthesis of nano-formulation loaded with doxorubicin 
 







spectral analysis. It was observed that the amount of 
Dox loaded was 22% of the total weight of the 
formulation. This formulation was evaluated for its 
cytotoxic ability against the RAJI-human 
hematopoietic origin cancer cell lines and WEHI-164 
mouse fibrosarcoma cell lines using flow cytometer. 
The formulation exhibited potential cytotoxicity as 
evidenced from flow cytometry (Fig. 5). In case of 
WEHI-164 cell lines 12% cell killing while in case of 
RAJI cancer cell lines 35% cell killing (IC50 ≈ 45 nM) 
when treated with the formulation nanomolar (nM) 
level of concentration of the formulation. From the 
results, it is evident that the formulation has the 
potential for the application in drug delivery and 
diagnosis in chemotherapeutics. 
 
 





Fig. 2 ― TEM images of (a) Mn doped ZnSe and (b) silica coated ZnSe:Mn NPs 
 
 
Fig. 4 ― Emission spectrum of ZnSe:Mn@mSilica-PEG-Tris-OH 
with 280 nm excitation 
 
 
Fig. 3 ― FT-IR spectra indicating the progress of surface
functionalization of ZnSe:Mn NPs 






We have synthesized ZnSe:Mn NPs coated with 
mesoporous silica which on further surface 
modifications to afforded amine functional groups. 
Further pegylation, followed by sequential treatment 
with acrylic acid followed by tris(hydroxymethyl-
aminomethane) to achieve the Tris fictionalized  
NPs, ZnSe:Mn@mSilica-PEG-Tris-OH. These NPs 
exhibited emission at 590 nm. Then the drug 
doxorubicin was loaded on ZnSe:Mn@mSilica-PEG-
Tris-OH through silyl ether linkage. This obtained 
formulation, MnZnSe@mSilica-PEG-Tris-O-Si(Me2)-
O-Dox was evaluated for the cytotoxicity against 
RAJI human hematopoietic origin and WEHI-164 
mouse fibrosarcoma cell lines which revealed potent 
cytotoxicity. From these results it is evident that the 
formulation has the potential for the application in 
drug delivery and diagnosis in cancer treatment.  
 
Supplementary Data 
The NMR [1H, 13C{1H}, 77Se{1H}] and FT-IR 
spectra for characterization (SeCH2CH2COOH)2 
(DSePA), FT-IR spectra for authentication of surface 
chemical modifications on NPs and flow cytometer 
graphs during cytotoxicity evaluation are given in the 
supplementary data. The supplementary data 
associated with this article are available in the 
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